Adult obesity and risk of severe infections: a multicohort study with global burden estimates
Adult obesity has been linked to specific infections, but evidence across the full spectrum of infectious diseases remains scarce.
Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus–Related Hospitalization
In this self-controlled case series study of 11 887 patients, the risk of cardiorespiratory events after RSV-related hospitalization was significantly higher than during the control period.
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study
Real-world evidence on nirsevimab impact beyond the first season when given under universal immunisation programmes is emerging.
Vaccination is vital to cardiovascular prevention, say heart specialists
The Society has published a Clinical Consensus Statement in the European Heart Journal highlighting the key role of vaccination in preventing cardiovascular events.
News
Policy & Recommendations
Winter Respiratory Viruses in Europe Policy Brief
In partnership with ESWI, the Coalition for Life Course Immunisation has released a new policy brief highlighting the urgent need for a more coordinated, life-course approach to respiratory virus prevention across the EU.
|
10th ESWI Influenza Conference 2025
When Infections Meet NCDs: The Bidirectional Relationship Between Cardiometabolic Conditions and Respiratory Viruses
Check out this Satellite Symposium organised by the ESWI IDC and supported by IFPMA and Sanofi from ESWI2026.
Impact and effectiveness of RSV maternal immunization on infant hospitalizations in Buenos Aires: a hospital-based, multicentre, retrospective surveillance cohort study
Respiratory syncytial virus (RSV) is a major cause of hospitalizations and mortality in young infants worldwide. The RSVpreF maternal immunization (MI) was recently introduced in Argentina.
Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
Passive immunisation with long-acting monoclonal antibodies (nirsevimab) targeting the two antigenic subgroups A and B of respiratory syncytial virus (RSV) was authorised by the European Medicines Agency for use in the European Union on 31 October 2022.
